121 related articles for article (PubMed ID: 11996485)
1. Reply to the article "Editorial comments on 'reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'", by P. A. Bunn Jr (Ann Oncol 2001; 12: 1339-1340).
Tjan-Heijnen VC; Postmus PE; Ardizzoni A;
Ann Oncol; 2002 Mar; 13(3):485-6; author reply 486-7. PubMed ID: 11996485
[No Abstract] [Full Text] [Related]
2. Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'.
Bunn PA
Ann Oncol; 2001 Oct; 12(10):1339-40. PubMed ID: 11762802
[No Abstract] [Full Text] [Related]
3. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.
Tjan-Heijnen VC; Postmus PE; Ardizzoni A; Manegold CH; Burghouts J; van Meerbeeck J; Gans S; Mollers M; Buchholz E; Biesma B; Legrand C; Debruyne C; Giaccone G;
Ann Oncol; 2001 Oct; 12(10):1359-68. PubMed ID: 11762805
[TBL] [Abstract][Full Text] [Related]
4. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).
Tjan-Heijnen VC; Caleo S; Postmus PE; Ardizzoni A; Burghouts JT; Buccholz E; Biesma B; Gorlia T; Crott R; Giaccone G; Debruyne C; Manegold C;
Ann Oncol; 2003 Feb; 14(2):248-57. PubMed ID: 12562652
[TBL] [Abstract][Full Text] [Related]
6. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
7. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
Ardizzoni A; Tjan-Heijnen VC; Postmus PE; Buchholz E; Biesma B; Karnicka-Mlodkowska H; Dziadziuszko R; Burghouts J; Van Meerbeeck JP; Gans S; Legrand C; Debruyne C; Giaccone G; Manegold C;
J Clin Oncol; 2002 Oct; 20(19):3947-55. PubMed ID: 12351591
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
9. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.
Ardizzoni A; Pennucci MC; Danova M; Viscoli C; Mariani GL; Giorgi G; Venturini M; Mereu C; Scolaro T; Rosso R
Br J Cancer; 1996 Oct; 74(7):1141-7. PubMed ID: 8855989
[TBL] [Abstract][Full Text] [Related]
12. High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide.
Soong D; Haj R; Leung MG; Myers R; Higgins B; Myers J; Rajagopal S
J Clin Oncol; 2009 Sep; 27(26):e101-2. PubMed ID: 19652050
[No Abstract] [Full Text] [Related]
13. [Small-cell lung carcinoma. Inappropriate antidiuretic hormone secretion revealed by chemotherapy].
Ploton C; Trillet V; Gharib C; Sassolas G; Yoanidis I; Bessonnat JF; Brune J
Presse Med; 1991 Mar; 20(12):562-3. PubMed ID: 1851988
[No Abstract] [Full Text] [Related]
14. The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization.
Avery RK; Pohlman BL; Mossad SB; Goormastic M; Longworth DL; Kalaycio ME; Sobecks RM; Andresen SW; Kuczkowski E; Bernhard L; Ostendorf H; Wise K; Bolwell BJ
Bone Marrow Transplant; 2002 Sep; 30(5):311-4. PubMed ID: 12209353
[TBL] [Abstract][Full Text] [Related]
15. Complications of treatment of small cell carcinoma of the lung. Experience from a recent Canadian trial.
Feld R; Payne D; Hodson I; Coy P
Antibiot Chemother (1971); 1988; 41():204-9. PubMed ID: 2854441
[No Abstract] [Full Text] [Related]
16. Assessing the relative effectiveness and tolerability of treatments in small cell lung cancer: a network meta-analysis.
Bakalos G; Miligkos M; Doxani C; Mpoulimari I; Rodopoulou P; Zintzaras E
Cancer Epidemiol; 2013 Oct; 37(5):675-82. PubMed ID: 23911891
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
18. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.
Jett JR; Everson L; Therneau TM; Krook JE; Dalton RJ; Marschke RF; Veeder MH; Brunk SF; Mailliard JA; Twito DI
J Clin Oncol; 1990 Jan; 8(1):33-8. PubMed ID: 2153193
[TBL] [Abstract][Full Text] [Related]
19. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.
Leighl NB; Burkes RL; Dancey JE; Lopez PG; Higgins BP; David Walde PL; Rudinskas LC; Rahim YH; Rodgers A; Pond GR; Shepherd FA
Clin Lung Cancer; 2003 Sep; 5(2):107-12. PubMed ID: 14596693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
